Short description
Vaxxinity is a biotechnology company that enables the innovation of synthetic peptide vaccines to prevent or treat infectious diseases.
Description
Vaxxinity, Inc. is a U.S.-based, clinical stage biotechnology company, that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. Vaxxinity has a proprietary technology platform that has enabled the innovation of synthetic peptide vaccines designed to treat and prevent chronic diseases, including Alzheimer's, Parkinson's, migraine, and hypercholesterolemia, as well as infectious diseases, including COVID-19. Vaxxinity has designed its pipeline to achieve a historic global impact on human health.
Last funding
Noway Youcantaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Dallas, Texas, United States, North America
Founded on
January 1, 2019
Exited on
November 11, 2021
Went public on
November 11, 2021
Stock symbol
VAXX
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noaccess, Cannot Access
Sign in for full access
Founders
Lou Reese, Mei Mei Hu, Peter Diamandis